The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

Abstract Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer treatment. Methods We examined data from Pu...

Full description

Bibliographic Details
Main Authors: Jingjie Chen, Shengnan Li, Qigu Yao, Nannan Du, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang
Format: Article
Language:English
Published: BMC 2020-07-01
Series:World Journal of Surgical Oncology
Subjects:
Nivolumab
Ipilimumab
Tumor response
Adverse events
Meta-analysis
Online Access:http://link.springer.com/article/10.1186/s12957-020-01933-5

Internet

http://link.springer.com/article/10.1186/s12957-020-01933-5

Similar Items